Targeting of MEK in lung cancer therapeutics

David F. Heigener, David R Gandara, Martin Reck

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


The MAP-kinase pathway, consisting of the kinases RAS, RAF, MEK, and ERK, is crucial for cell proliferation, inhibition of apoptosis, and migration of cells. Direct inhibition of RAS is not yet possible, whereas inhibition of RAF is already established in malignant melanoma and under investigation in non-small-cell lung cancer (NSCLC). Due to their structure and function, the MEK proteins are attractive targets for cancer therapy and are also under investigation in NSCLC. We discuss strategies of targeting the RAS-RAF-MEK-ERK pathway with emphasis on MEK inhibition, either alone or in combination with other targets or conventional chemotherapy.

Original languageEnglish (US)
Pages (from-to)319-327
Number of pages9
JournalThe Lancet Respiratory Medicine
Issue number4
StatePublished - Apr 1 2015

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Targeting of MEK in lung cancer therapeutics'. Together they form a unique fingerprint.

Cite this